These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19422008)

  • 1. Engineered two-helix small proteins for molecular recognition.
    Webster JM; Zhang R; Gambhir SS; Cheng Z; Syud FA
    Chembiochem; 2009 May; 10(8):1293-6. PubMed ID: 19422008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of an optimized scaffold for affibody molecules.
    Feldwisch J; Tolmachev V; Lendel C; Herne N; Sjöberg A; Larsson B; Rosik D; Lindqvist E; Fant G; Höidén-Guthenberg I; Galli J; Jonasson P; Abrahmsén L
    J Mol Biol; 2010 Apr; 398(2):232-47. PubMed ID: 20226194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
    Wållberg H; Löfdahl PK; Tschapalda K; Uhlén M; Tolmachev V; Nygren PK; Ståhl S
    Protein Expr Purif; 2011 Mar; 76(1):127-35. PubMed ID: 21029777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular evolution of cystine-stabilized miniproteins as stable proteinaceous binders.
    Chang HJ; Hsu HJ; Chang CF; Peng HP; Sun YK; Yu HM; Shih HC; Song CY; Lin YT; Chen CC; Wang CH; Yang AS
    Structure; 2009 Apr; 17(4):620-31. PubMed ID: 19368895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold.
    Nygren PA
    FEBS J; 2008 Jun; 275(11):2668-76. PubMed ID: 18435759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitored whole gene in vitro evolution of an anti-hRaf-1 affibody molecule towards increased binding affinity.
    Grimm S; Salahshour S; Nygren PÅ
    N Biotechnol; 2012 Jun; 29(5):534-42. PubMed ID: 22027369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for molecular recognition in an affibody:affibody complex.
    Lendel C; Dogan J; Härd T
    J Mol Biol; 2006 Jun; 359(5):1293-304. PubMed ID: 16750222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From synthetic coiled coils to functional proteins: automated design of a receptor for the calmodulin-binding domain of calcineurin.
    Ghirlanda G; Lear JD; Lombardi A; DeGrado WF
    J Mol Biol; 1998 Aug; 281(2):379-91. PubMed ID: 9698554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.
    Vernet E; Konrad A; Lundberg E; Nygren PA; Gräslund T
    J Immunol Methods; 2008 Sep; 338(1-2):1-6. PubMed ID: 18671978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A designed ankyrin repeat protein evolved to picomolar affinity to Her2.
    Zahnd C; Wyler E; Schwenk JM; Steiner D; Lawrence MC; McKern NM; Pecorari F; Ward CW; Joos TO; Plückthun A
    J Mol Biol; 2007 Jun; 369(4):1015-28. PubMed ID: 17466328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystal structure of engineered beta-glucosidase from a soil metagenome.
    Nam KH; Kim SJ; Kim MY; Kim JH; Yeo YS; Lee CM; Jun HK; Hwang KY
    Proteins; 2008 Nov; 73(3):788-93. PubMed ID: 18712828
    [No Abstract]   [Full Text] [Related]  

  • 12. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.
    Löfblom J; Feldwisch J; Tolmachev V; Carlsson J; Ståhl S; Frejd FY
    FEBS Lett; 2010 Jun; 584(12):2670-80. PubMed ID: 20388508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfide bond substitution by directed evolution in an engineered binding protein.
    Drevelle A; Urvoas A; Hamida-Rebaï MB; Van Vooren G; Nicaise M; Valerio-Lepiniec M; Desmadril M; Robert CH; Minard P
    Chembiochem; 2009 May; 10(8):1349-59. PubMed ID: 19415706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full-sequence computational design and solution structure of a thermostable protein variant.
    Shah PS; Hom GK; Ross SA; Lassila JK; Crowhurst KA; Mayo SL
    J Mol Biol; 2007 Sep; 372(1):1-6. PubMed ID: 17628593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody.
    Ekblad T; Tolmachev V; Orlova A; Lendel C; Abrahmsén L; Karlström AE
    Biopolymers; 2009; 92(2):116-23. PubMed ID: 19140162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered affinity proteins--generation and applications.
    Grönwall C; Ståhl S
    J Biotechnol; 2009 Mar; 140(3-4):254-69. PubMed ID: 19428722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-associated substitutions in the filamin B actin binding domain confer enhanced actin binding affinity in the absence of major structural disturbance: Insights from the crystal structures of filamin B actin binding domains.
    Sawyer GM; Clark AR; Robertson SP; Sutherland-Smith AJ
    J Mol Biol; 2009 Jul; 390(5):1030-47. PubMed ID: 19505475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering of affibody molecules for therapy and diagnostics.
    Feldwisch J; Tolmachev V
    Methods Mol Biol; 2012; 899():103-26. PubMed ID: 22735949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Creation of a new eye lens crystallin (Gambeta) through structure-guided mutagenic grafting of the surface of betaB2 crystallin onto the hydrophobic core of gammaB crystallin.
    Kapoor D; Singh B; Subramanian K; Guptasarma P
    FEBS J; 2009 Jun; 276(12):3341-53. PubMed ID: 19438717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.